Chemical formula: C₂₈H₃₀N₂O₂  Molecular mass: 426.55 g/mol  PubChem compound: 444031

Active ingredient description

Darifenacin is a selective muscarinic M3 receptor antagonist (M3 SRA) in vitro. The M3 receptor is the major subtype that controls urinary bladder muscle contraction. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
G04BD10 Darifenacin G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BD Urinary antispasmodics
Discover more medicines within G04BD10

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
ENABLEX Extended-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
EMSELEX Prolonged-release tablet European Medicines Agency (EU) MPI, EU: SmPC

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 133099-04-4
DrugBank Drug: DB00496
KEGG Drug: D01699
PubChem Compound: 444031
RxNorm Ingredient: 136198
SNOMED-CT Concept: 416140008
Darifenacin (substance)
UNII Identifier: APG9819VLM

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.